Advertisement
Advertisement

LEXX

LEXX logo

Lexaria Bioscience Corp. Common Stock

0.58
USD
Sponsored
+0.04
+7.89%
Jun 22, 15:52 UTC -4
Closed
exchange

After-Market

0.57

-0.01
-2.37%

LEXX Earnings Reports

Positive Surprise Ratio

LEXX beat 7 of 16 last estimates.

44%

Next Report

Date of Next Report
Jul 13, 2026
Estimate for Q3 26 (Revenue/ EPS)
$51.00K
/
-$0.08
Implied change from Q2 26 (Revenue/ EPS)
+155.00%
/
+33.33%
Implied change from Q3 25 (Revenue/ EPS)
-70.69%
/
-61.90%

Lexaria Bioscience Corp. Common Stock earnings per share and revenue

On Apr 13, 2026, LEXX reported earnings of -0.06 USD per share (EPS) for Q2 26, beating the estimate of -0.09 USD, resulting in a 38.08% surprise. Revenue reached 20.00 thousand, compared to an expected 51.00 thousand, with a -60.78% difference. The market reacted with a +7.69% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.08 USD, with revenue projected to reach 51.00 thousand USD, implying an increase of 33.33% EPS, and increase of 155.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
logo
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
logo
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
logo
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
FAQ
For Q2 2026, Lexaria Bioscience Corp. Common Stock reported EPS of -$0.06, beating estimates by 38.08%, and revenue of $20.00K, -60.78% below expectations.
The stock price moved up 7.69%, changed from $0.91 before the earnings release to $0.98 the day after.
The next earning report is scheduled for Jul 13, 2026.
Based on 3 analysts, Lexaria Bioscience Corp. Common Stock is expected to report EPS of -$0.08 and revenue of $51.00K for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement